Evaluate the effect of TECAR therapy on pain, voiding, erectile function, sleep quality and quality of life in men with chronic prostatitis/chronic pelvic pain syndrome.
Sixty men with chronic prostatitis/chronic pelvic pain will be sourced from the urology outpatient clinic at Tanta University hospitals in Egypt, with referrals from urologists. Patients will be randomly assigned into two groups. Study group: It will include 30 men receiving true TECAR therapy plus dietary and life style adjustments. Control group: It will include 30 men receiving sham TECAR therapy plus dietary and life style adjustments. Evaluation Procedures: 1. Pain, voiding, and quality of life using the National Institutes of Health-Chronic Prostatitis Symptom Index. 2. Sleep quality using the Pittsburgh Sleep Quality Index. 3. Erectile function using the International Index of Erectile Function.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
60
WINBACK 3SE (France) will be used for TECAR therapy in this study. To facilitate optimal distribution of endogenous heat therapy and effective contact between the active electrodes, both capacitive and resistive, and the surface of the skin, a layer of high-conductivity cream will be applied to the treatment region. The plate, an inactive electrode, which has a specific size (21cm\*15cm), will be placed on the gluteal region. The capacitive electrode was employed for a duration of seven and a half minutes, at an intensity of 30-40%, whereas the resistance electrode will be utilized for an equivalent period over the perineum at the same intensity.
The procedure is similar to the active treatment of TECAR, but with the critical difference being that the output intensity of the TECAR device will be set to zero during the session.
Tanta University Hospital
Tanta, Egypt
Pelvic pain
Pain will be assessed using the National Institutes of Health-Chronic Prostatitis Symptom Index
Time frame: Baseline and 8 weeks later
Quality of life of men
Quality of life will be assessed using the National Institutes of Health-Chronic Prostatitis Symptom Index
Time frame: Baseline and after 8 weeks
Mohammed Elhamrawy, Ph.D
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.